Gilead patent expiration

1. Cayston patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7208141 GILEAD Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

US7427633 GILEAD Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

US7214364 GILEAD Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)

US8399496 GILEAD Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Dec, 2021

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Feb 22, 2017

Drugs and Companies using AZTREONAM ingredient

Market Authorisation Date: 22 February, 2010

Treatment: Improve respiratory symptoms in cystic fibrosis in patients with pseudomonas aeruginosa

Dosage: FOR SOLUTION

More Information on Dosage

CAYSTON family patents

Family Patents

2. Emtriva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5814639 GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5814639

(Pediatric)

GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Mar, 2016

(8 years ago)

US5914331 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(7 years ago)

US5914331

(Pediatric)

GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jan, 2018

(6 years ago)

US6642245 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US6703396 GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

US6642245

(Pediatric)

GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
May, 2021

(3 years ago)

US6703396

(Pediatric)

GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Sep, 2021

(2 years ago)




Drugs and Companies using EMTRICITABINE ingredient

Market Authorisation Date: 28 September, 2005

Treatment: Method of treatment of adults infected with hiv-1

Dosage: SOLUTION; CAPSULE

How can I launch a generic of EMTRIVA before it's drug patent expiration?
More Information on Dosage

EMTRIVA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Hepsera patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5663159 GILEAD Prodrugs of phosphonates
Sep, 2014

(9 years ago)

US6451340 GILEAD Nucleotide analog compositions
Jul, 2018

(5 years ago)




Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient

Market Authorisation Date: 20 September, 2002

Treatment: Therapy in chronic hepatitis b virus infection

Dosage: TABLET

How can I launch a generic of HEPSERA before it's drug patent expiration?
More Information on Dosage

HEPSERA family patents

Family Patents

4. Letairis patent expiration

LETAIRIS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5703017 GILEAD 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation
Dec, 2014

(9 years ago)

US7601730 GILEAD Carboxylic acid derivatives, their preparation and use
Oct, 2015

(8 years ago)

US8349843 GILEAD Carboxylic acid derivatives, their preparation and use
Oct, 2015

(8 years ago)

US7109205 GILEAD Carboxylic acid derivatives, their preparation and use
Oct, 2015

(8 years ago)

US5840722 GILEAD Use of carboxylic acid derivatives as drugs
Nov, 2015

(8 years ago)

USRE42462 GILEAD Carboxylic acid derivatives, their preparation and use
Jul, 2018

(5 years ago)

US9474752 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(3 years from now)

US8377933 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(3 years from now)

US9549926 GILEAD Compositions and methods of treating pulmonary hypertension
Oct, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 15, 2012
Orphan Drug Exclusivity(ODE) Jun 15, 2014
New Indication(I-716) Oct 02, 2018

Drugs and Companies using AMBRISENTAN ingredient

NCE-1 date: 16 June, 2011

Market Authorisation Date: 15 June, 2007

Treatment: Method to treat pulmonary hypertension by administering ambrisentan to a patient; Treatment of pulmonary arterial hypertension by inhibiting endothelin receptors; For the treatment of pulmonary hypert...

Dosage: TABLET

How can I launch a generic of LETAIRIS before it's drug patent expiration?
More Information on Dosage

LETAIRIS family patents

Family Patents

5. Truvada patent expiration

TRUVADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5814639 GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5914331 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(7 years ago)

US5922695 GILEAD Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US5935946 GILEAD Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

US5977089 GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US6703396 GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5814639 GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5814639

(Pediatric)

GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Mar, 2016

(8 years ago)

US5914331 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(7 years ago)

US6043230 GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5977089 GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5922695 GILEAD Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US5935946 GILEAD Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

US5914331

(Pediatric)

GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jan, 2018

(6 years ago)

US5922695

(Pediatric)

GILEAD Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jan, 2018

(6 years ago)

US6043230

(Pediatric)

GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US5977089

(Pediatric)

GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US5935946

(Pediatric)

GILEAD Nucleotide analog composition and synthesis method
Jan, 2018

(6 years ago)

US6642245 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US6703396 GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

US6642245

(Pediatric)

GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
May, 2021

(3 years ago)

US6703396

(Pediatric)

GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Sep, 2021

(2 years ago)

US9744181 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(6 months ago)

US8716264 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(6 months ago)

US8592397 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(6 months ago)

US9457036 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(6 months ago)

US8716264

(Pediatric)

GILEAD Compositions and methods for combination antiviral therapy
Jul, 2024

(5 days ago)




Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: Treatment of hiv; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Method of treatment of adults infected with hiv-1; Treatment of hiv infection; Prophylaxis of hiv-1 infe...

Dosage: TABLET

How can I launch a generic of TRUVADA before it's drug patent expiration?
More Information on Dosage

TRUVADA family patents

Family Patents